Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 201–300 of 899
Weng, T., Wu, H. F., Li, C.-Y., Hung, Y.-H., Chang, Y.-W., Chen, Y., Hsu, H., Chen, Y.-H., Wang, C., Chang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26454-w · Cited by 48
Ye, Q., Zhang, Y., Cao, Y., Wang, X., Guo, Y., Chen, J., Horn, J., Ponomareva, L. V., Chaiswing, L., Shaaban, K. A., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.013 · Cited by 48
“Recent work suggests that targeting cap-dependent translation may overcome intra-tumor heterogeneity-mediated resistance and provide a promising strategy for improving cancer therapy (Bhat et al., 2015; Boussemart et al., 2014; Cai et al., 2014; Ducker et al., 2014; Hsieh et al., 2010; Mi et al., 2015; She et al., 201…”
BackgroundTan, Q., Wang, D., Yang, J., Xing, P., Yang, S., Li, Y., Qin, Y., He, X., Liu, Y., Zhou, S., et al. (2020) · Theranostics · doi:10.7150/thno.45816 · Cited by 48
“EIF4E plays a vital role in cap-dependent translation of cellular mRNAs, and influences a subset of mRNAs encoding oncogenic proteins, such as vascular endothelial growth factor (VEGF), MYC, and cyclins [42].”
BackgroundNaineni, S. K., Liang, J., Hull, K. G., Cencic, R., Zhu, M., Northcote, P. T., Teesdale‐Spittle, P. H., Romo, D., Nagar, B., & Pelletier, J. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.006 · Cited by 48
“Among the mRNAs that show a higher dependence on eIF4F for initiation, several fuel hallmarks of cancer, making eIF4F and eIF4A targets for drug development (Bhat et al., 2015).”
BackgroundSelf-citationLi, Z., Sun, Y., Qu, M., Wan, H., Cai, F., & Zhang, P. (2016) · Oncotarget · doi:10.18632/oncotarget.13772 · Cited by 48
“eIF4E overexpression/ activation correlates with poor clinical outcome in human cancers as it promotes the translation of carcinogenesis associated mRNAs [5, 6].”
BackgroundCodon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Ali, M., Kaltenbrun, E., Anderson, G. R., Stephens, S. J., Arena, S., Bardelli, A., Counter, C. M., & Wood, K. C. (2017) · Nature Communications · doi:10.1038/ncomms15617 · Cited by 43
“These findings, along with data showing that cancer cells co-opt translational machinery to support tumour growth, have driven increased interest in targeting translational control as a method to selectively kill cancer cells 46 .”
The Role of Obesity in Breast Cancer Pathogenesis
Glassman, I., Le, N., Asif, A., Goulding, A., Alcantara, C. A., Vu, A., Chorbajian, A., Mirhosseini, M., Singh, M., & Venketaraman, V. (2023) · Cells · doi:10.3390/cells12162061 · Cited by 47
“Following activation by the PI3K/AKT pathway, mTORC1 regulates the assembly of the eukaryotic translation initiation factor 4F (elF4F) complex by mediating phosphorylation of 4E-binding proteins (4EBP1), as well as the activation of ribosomal protein S6 kinase 1 (p70S6K) [128].”
BackgroundInfluentialBeyond molecular tumor heterogeneity: protein synthesis takes control
y Cajal, S. R., Castellví, J., Hümmer, S., Peg, V., Pelletier, J., & Sonenberg, N. (2018) · Oncogene · doi:10.1038/s41388-018-0152-0 · Cited by 47
“[33]) are directed against, the expression of eIF4E [75, 76], the interaction between eIF4E-4G [77, 78], the binding of eIF4F complex to the 5′-cap structure [79, 80], the eIF4A helicase activity [81–84], the phosphorylation status of eIF2α [85, 86], and the kinase activity of MNK1/2 [87–91].”
BackgroundSelf-citationThe impact of phosphatases on proliferative and survival signaling in cancer
Narla, G., Sangodkar, J., & Ryder, C. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2826-8 · Cited by 47
“) its translation is cap dependent [114].”
Chen, Y., Chang, Y., & Huang, Y. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22653 · Cited by 47
Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling
Zou, Q., Xiao, Z., Huang, R., Wang, X., Wang, X., Zhao, H., & Yang, X. (2019) · Theranostics · doi:10.7150/thno.35033 · Cited by 47
“It has long been recognized that translation dysregulation is a signature feature and potential driver of tumorigenesis, as many translation initiation factors and up-stream signaling regulators of translation bear extensive genetic alterations in cancers [1, 2].”
BackgroundBanna, N. E., Hatem, E., Heneman-Masurel, A., Léger, T., Baïlle, D., Vernis, L., Garcia, C., Martineau, S., Dupuy, C., Vagner, S., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101290 · Cited by 47
“It is worth noting that since recognizing the important role played by deregulated translation in carcinogenesis [42], the repression or blockage of protein synthesis has gained a significant interest as a promising anticancer strategy [43,44].”
BackgroundKong, T., Xue, Y., Cencic, R., Zhu, X., Monast, A., Fu, Z., Pilon, V., Sangwan, V., Guiot, M., Foulkes, W. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0162 · Cited by 47
“Therefore, silvestrol and CR-1-31-B, while also being well tolerated in animals, suppress translation of these oncogenic mRNAs and block proliferation in breast, prostate, lymphoma, and acute lymphoblastic leukemia cancer models (15, 22, 23, 25).”
BackgroundSelf-citationTranslational remodeling by RNA ‐binding proteins and noncoding RNAs
Ho, J. J. D., Man, J. H. S., Schatz, J. H., & Marsden, P. A. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1647 · Cited by 47
“Protein synthesis is a critical convergence point of myriad upstream signaling inputs, and thus targeted translational modulation represents an attractive therapeutic strategy (Bhat et al., 2015; Chu & Pelletier, 2018; Truitt & Ruggero, 2016) that can bypass signaling redundancies that restrict the efficacy of many ex…”
BackgroundTargeting translation: a promising strategy for anticancer metallodrugs
Ortega, E., Vigueras, G., Ballester, F. J., & Ruiz, J. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214129 · Cited by 47
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression
Gassart, A. D., Demaria, O., Panès, R., Zaffalon, L., Ryazanov, A. G., Gilliet, M. F., & Martinon, F. (2016) · EMBO Reports · doi:10.15252/embr.201642194 · Cited by 47
“Therefore, therapeutic agents that target components of the translation machinery to decrease translation rates hold promise as broad activity anticancer drugs that could overcome intra-tumor heterogeneity [48].”
Therapeutic Opportunities in Eukaryotic Translation
Chu, J., & Pelletier, J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032995 · Cited by 47
“, c-MYC, cyclins, ornithine decarboxylase [ODC], BCL-2, MCL-1, BCL-XL, osteopontin, survivin, vascular endothelial growth factor [VEGF], fibroblast growth factors [FGF]) (Colina et al. 2008; Mills et al. 2008; Petroulakis et al. 2009; Dowling et al. 2010; Bhat et al. 2015; Chu et al. 2016a).”
BackgroundInfluentialSelf-citationTherapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 46
A comparative study of small molecules targeting eIF4A
Naineni, S. K., Maïga, R. I., Cencic, R., Putnam, A. A., Amador, L. A., Rodríguez, A. D., Jankowsky, E., & Pelletier, J. (2020) · RNA · doi:10.1261/rna.072884.119 · Cited by 46
“Small molecules that inhibit eIF4F activity have been identified from highthroughput screens, and among the more potent ones are those that target eIF4A—namely hippuristanol (Hipp), rocaglates, and pateamine A (Cencic et al. 2012; Bhat et al. 2015; Chu and Pelletier 2015).”
BackgroundSelf-citationComputational resources for ribosome profiling: from database to Web server and software
Wang, H., Wang, Y., & Xie, Z. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx093 · Cited by 45
“Emerging evidence has shown that targeting components of translation apparatus may be a promising strategy for disease treatment [4, 5].”
Backgroundc-MYC regulates mRNA translation efficiency and start-site selection in lymphoma
Singh, K., Lin, J., Zhong, Y., Burčul, A., Mohan, P., Jiang, M., Sun, L. L., Yong‐Gonzalez, V., Viale, A. J., Cross, J. R., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181726 · Cited by 45
“These have been largely attributed to activation of the mTOR/4EBP1/eIF4E signaling axis that acts as a driver of an anabolic and growth-promoting translation program that includes the translation of a subset of mRNA encoding mitochondrial proteins in an eIF4E-dependent manner and that is opposed by the catabolic effec…”
BackgroundControl of Translation at the Initiation Phase During Glucose Starvation in Yeast
Janapala, Y., Preiß, T., & Shirokikh, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164043 · Cited by 45
Müller, D., Shin, S., Goullet de Rugy, T., Samain, R., Baer, R., Strehaiano, M., Masvidal-Sanz, L., Guillermet-Guibert, J., Jean, C., Tsukumo, Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121951 · Cited by 43
Self-citationBi-directional ribosome scanning controls the stringency of start codon selection
Gu, Y., Mao, Y., Jia, L., Dong, L., & Qian, S. (2021) · Nature Communications · doi:10.1038/s41467-021-26923-3 · Cited by 45
Waldron, J. A., Raza, F., & Quesne, J. P. C. L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky108 · Cited by 45
“The eIF4F complex is situated at the nexus of many mitogenic signalling pathways (5,6), where it exerts pervasive control over mRNA translation.”
BackgroundMurata, K., Lu, W., Hashimoto, M., Ono, N., Muratani, M., Nishikata, K., Kim, J., Ebihara, S., Ishida, J., & Fukamizu, A. (2018) · iScience · doi:10.1016/j.isci.2018.09.023 · Cited by 45
Zhang, L., & Min, W. (2017) · Journal of Biomedical Optics · doi:10.1117/1.jbo.22.10.106010 · Cited by 44
“cells, this process is dysregulated in cancer cells, leading to fast and uncontrolled protein synthesis.(6) Glucose uptake is also gen-”
BackgroundBEZ235: When Promising Science Meets Clinical Reality
Pongas, G., & Fojo, T. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0243 · Cited by 43
Sequence features of viral and human Internal Ribosome Entry Sites predictive of their activity
Gritsenko, A. A., Weingarten-Gabbay, S., Elias‐Kirma, S., Nir, R., de Ridder, D., & Segal, E. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005734 · Cited by 43
“Once the AUG is found in a favourable context, the 60S ribosomal subunit is assembled on the mRNA to begin protein synthesis [1, 2].”
BackgroundKelly, N. J., Varga, J. F. A., Specker, E. J., Romeo, C. M., Coomber, B. L., & Uniacke, J. (2017) · Oncogene · doi:10.1038/onc.2017.372 · Cited by 43
Nutrient Control of mRNA Translation
Shu, X. E., Swanda, R. V., & Qian, S. (2020) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120919-041411 · Cited by 43
“Dysregulation of mRNA translation is frequently observed cancer cells (12, 145, 157).”
BackgroundLi, S., Shao, J., Lou, G., Wu, C., Liu, Y., & Zheng, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01853-6 · Cited by 43
Afzal, O., Altamimi, A. S. A., Mubeen, B., Alzarea, S. I., Almalki, W. H., Al-Qahtani, S. D., Atiya, E. M., Al-Abbasi, F. A., Ali, F., Ullah, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012470 · Cited by 43
Targeting MYC Translation in Colorectal Cancer
Castell, A., & Larsson, L. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0660 · Cited by 43
Feng, Y., Pinkerton, A. B., Hulea, L., Zhang, T., Davies, M. A., Grotegut, S., Chéli, Y., Yin, H. H., Lau, E. K., Kim, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0885 · Cited by 43
“in cells that exhibit high eIF4E–4E-BP ratio and correlates with their inability to disrupt the eIF4F complex (14).”
Self-citationExpression and activity of eIF6 trigger Malignant Pleural Mesothelioma growthin vivo
Miluzio, A., Oliveto, S., Pesce, E., Mutti, L., Murer, B., Grosso, S., Ricciardi, S., Brina, D., & Biffo, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5462 · Cited by 42
“Recent works have shown that the translational machinery plays an active role in transformation and tumor malignancy, suggesting that it can be a therapeutic target [3, 4].”
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer
Hsu, J. H.-R., Hubbell-Engler, B., Adelmant, G., Huang, J., Joyce, C. E., Vázquez, F., Weir, B. A., Montgomery, P. G., Tsherniak, A., Giacomelli, A. O., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0216 · Cited by 42
“Deregulation of ribosomal proteins and translation initiation factors, including the eIF4F complex, among others, have been shown to contribute to tumor development(4,5).”
BackgroundMyc, Oncogenic Protein Translation, and the Role of Polyamines
Franson, A. T., & Hogarty, M. D. (2018) · Medical Sciences · doi:10.3390/medsci6020041 · Cited by 42
“Deregulated protein synthesis is a common feature of human cancers, and recent work has led to a more complete understanding of how qualitative and quantitative alterations in translation control are sentinel to cancer development, maintenance, and progression [13,14].”
BackgroundHerrmannová, A., Prilepskaja, T., Wagner, S., Šikrová, D., Zeman, J., Poncová, K., & Valášek, L. S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1185 · Cited by 42
“(some eIF3 subunits were even suggested to serve as oncogenes or tumor suppressors with potential prognostic values), as well as recent observations that eIF3 can drive alternative modes of initiation in mRNA-specific manner (1,2,35,36), it will be intriguing to investigate the ability of all so far identified partial…”
BackgroundRecent advancements in mass spectrometry–based tools to investigate newly synthesized proteins
van Bergen, W., Heck, A. J. R., & Baggelaar, M. P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.07.001 · Cited by 41
Lamaudière, M. T. F., Arasaradnam, R. P., Weedall, G. D., & Morozov, I. Y. (2023) · mSphere · doi:10.1128/msphere.00627-22 · Cited by 42
“expression, including translation (59).”
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment
Bartish, M., Abraham, M. J., Gonçalves, C., Larsson, O. S., Rolny, C., & Rincon, S. V. D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00567-5 · Cited by 42
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia
Kościuczuk, E. M., Saleiro, D., & Platanias, L. C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.024 · Cited by 42
“Unfortunately, the efficacy of rapamycin analogs in leukemia treatment has been clinically lower than expected [11,72,73].”
InfluentialBRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Kurata, K., Samur, M., Liow, P., Wen, K., Yamamoto, L., Liu, J., Morelli, E., Gullà, A., Tai, Y., Qi, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3668 · Cited by 41
Non-canonical mRNA translation initiation in cell stress and cancer
Mahé, M., Rios-Fuller, T. J., Katsara, O., & Schneider, R. J. (2024) · NAR Cancer · doi:10.1093/narcan/zcae026 · Cited by 41
Yu, Y., Tian, L., Xiao, F., Cheng, J. Q., Gong, Y., Liu, X., Zhang, Z., Yang, X., He, S., Li, C., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.052 · Cited by 41
“Translational control of malignancy-related mRNAs has been considered as a major part in malignant progression [12,13].”
BackgroundDifferential Sensitivity of Target Genes to Translational Repression by miR-17~92
Jin, H. Y., Oda, H., Chen, P., Yang, C., Zhou, X., Kang, S. G., Valentine, E., Kefauver, J. M., Liao, L., Zhang, Y., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006623 · Cited by 41
“We also measured the protein levels of 16 genes that control translation initiation and elongation in a global manner and completely lack miR-17~92 binding sites in their mRNAs [70].”
MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
Guo, Q., Li, V. Z., Nichol, J. N., Huang, F., Yang, W., Preston, S. E. J., Talat, Z., Lefrère, H., Yu, H. G., Zhang, G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1602 · Cited by 42
“Next, we tested the role that VIMENTIN might play in the increased invasion seen in cells that express a constitutively activated MNK1 (caMNK1).”
BackgroundInfluentialTaroncher‐Oldenburg, G., Müller, C., Obermann, W., Ziebuhr, J., Hartmann, R. K., & Grünweller, A. (2021) · Microorganisms · doi:10.3390/microorganisms9030540 · Cited by 41
m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance
Chen, C., Guo, Y., Guo, Y., Wu, X., Si, C., Xu, Y., Kang, Q., & Sun, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746789 · Cited by 41
“Promoting RNA Translation for Cancer Drug Resistance Dysregulation RNA translation was found in multiple diseases, including cancer (88, 89).”
BackgroundZhang, L., Hapon, M. B., Goyeneche, A. A., Srinivasan, R., Gamarra-Luques, C. D., Callegari, E. A., Drappeau, D. D., Terpstra, E. J. M., Pan, B., Knapp, J. R., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.001 · Cited by 41
Wang, J., Farris, A. B., Xu, K., Wang, P., Zhang, X., Duong, D. M., Yi, H. L., Shu, H. G., Sun, S., & Wang, Y. (2016) · Nature Communications · doi:10.1038/ncomms11795 · Cited by 40
“21).”
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
Latosińska, A., Mokou, M., Makridakis, M., Mullen, W., Zoidakis, J., Lygirou, V., Frantzi, M., Katafigiotis, I., STRAVODIMOS, K. G., Hupe, M. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17279 · Cited by 40
“Aberrant expression, mutations and post-translational modifications of many translation initiation factors have been previously described in different cancer types [50, 80].”
BackgroundThe Plasticizer Bisphenol A Perturbs the Hepatic Epigenome: A Systems Level Analysis of the miRNome
Renaud, L., da Silveira, W. A., Hazard, E. S., Simpson, J., Falcinelli, S., Chung, D., Carnevali, O., & Hardiman, G. (2017) · Genes · doi:10.3390/genes8100269 · Cited by 40
“The ToppFun functional enrichment analysis suggests that exposure to BPA impaires processes such as transcription/translation, cell cycle progression and mitochondrial function, all of which are involved during the development and progression of cancers [107–109].”
Dunn, S., Lombardi, O., Lukoszek, R., & Cowling, V. H. (2019) · Open Biology · doi:10.1098/rsob.190052 · Cited by 40
The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Wood, S., Willbanks, A. R., & Cheng, J. X. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210127092828 · Cited by 40
Nsp3-N interactions are critical for SARS-CoV-2 fitness and virulence
Li, P., Xue, B., Schnicker, N., Wong, L.-Y. R., Meyerholz, D. K., & Perlman, S. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305674120 · Cited by 40
“These cells, which are immortalized, are expected to express high levels of translation factors such as eIF4G and eIF4E (16).”
Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells
Choi, Y. J., Lee, Y. S., Lee, H. W., Shim, D. M., & Seo, S. W. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.63.bjr-2016-0151.r2 · Cited by 39
KDM5A Regulates a Translational Program that Controls p53 Protein Expression
Hu, D., Jablonowski, C. M., Cheng, P.-H., AlTahan, A. M., Li, C., Wang, Y., Palmer, L. E., Lan, C., Sun, B., Abu‐Zaid, A., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.012 · Cited by 38
Autophagy Regulation by the Translation Machinery and Its Implications in Cancer
Acevo-Rodríguez, P. S., Maldonado, G., Castro‐Obregón, S., & Hernández, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00322 · Cited by 38
Oblinger, J. L., Burns, S. S., Akhmametyeva, E. M., Huang, J., Li, P., Ren, Y., Shen, R. Z., Miles‐Markley, B. A., Moberly, A. C., Kinghorn, A. D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now032 · Cited by 38
“The high eIF4E expression is associated with malignant progression and poor prognosis in several types of cancers.(3) Increased eIF4A levels also correlate with poor survival in estrogen receptor-negative breast cancer.”
BackgroundCrosstalks between translation and metabolism in cancer
Biffo, S., Manfrini, N., & Ricciardi, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.011 · Cited by 38
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas
Zhang, X., Bi, C., Lu, T., Zhang, W., Yue, T., Wang, C., Tian, T., Zhang, X., Huang, Y., Lunning, M. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0503-z · Cited by 38
Cuesta, R., & Holz, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8375 · Cited by 37
“Deregulation of eIF4F is observed in many cancers, and results in increased translation of specific mRNAs that encode for proteins involved in the regulation of cellular growth and proliferation, enhanced survival, migration, and invasion [28, 29].”
BackgroundMelanson, G., Timpano, S., & Uniacke, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6098107 · Cited by 38
“Constitutively active mTORC1 causes eIF4E-driven translation to be hyperactive in most cancers and is currently a major target of cancer therapeutics (reviewed in [19]).”
BackgroundInfluentialKwegyir‐Afful, A. K., Ramalingam, S., Ramamurthy, V. P., Purushottamachar, P., Murigi, F. N., Vasaitis, T. S., Huang, W., Kane, M. A., Zhang, Y., Ambulos, N. P., et al. (2019) · Cancers · doi:10.3390/cancers11111637 · Cited by 37
Gong, Q., Ali, T., Hu, Y., Gao, R., Mou, S., Luo, Y., Yang, C., Li, A., Li, T., Hao, L., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01796-3 · Cited by 36
“In addition, RIPK1 enhances the transcription of inflammatory cytokines through activation of the eIF4E-mediated cap-dependent translation initiation process [18, 19].”
BackgroundFooks, K., Galicia-Vázquez, G., Gife, V., Schcolnik‐Cabrera, A., Nouhi, Z., Poon, W. W. L., Luo, V. M., Rys, R. N., Aloyz, R. S., Orthwein, A., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02542-8 · Cited by 37
Self-citationATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A
Tillotson, J., Kędzior, M., Guimarães, L. A., Ross, A. B., Peters, T. L., Ambrose, A. J., Schmidlin, C. J., Zhang, D. D., Costa-Lotufo, L. V., Rodríguez, A. D., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.045 · Cited by 36
Oh, T.-I., Lee, Y.-M., Nam, T.-J., Ko, Y. S., Mah, S., Kim, J., Kim, Y.-H., Rallabandi, H. R., Kim, Y. J., Hong, S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102074 · Cited by 36
Gendron, J. M., Webb, K. J., Yang, B., Rising, L., Zuzow, N., & Bennett, E. J. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058420 · Cited by 35
“This observation suggests that the acquisition of an elevated protein homeostasis capacity may be a key event during tumorigenesis (14, 15).”
BackgroundMNK2 governs the macrophage antiinflammatory phenotype
Bartish, M., Tong, D., Pan, Y., Wallerius, M., Liu, H., Ristau, J., Ferreira, S. D. S., Wallmann, T., van Hoef, V., Masvidal, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920377117 · Cited by 36
“However, the discrepancy is consistent with mRNA translation as commonly modulated by factors in the tumor microenvironment (13, 39), which are absent under in vitro conditions.”
BackgroundTumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics
Phan, T. T. T., Lin, Y., Chou, Y., Wu, C., & Lin, L. (2022) · Oncogenesis · doi:10.1038/s41389-022-00401-x · Cited by 35
“This underscores components of the mTORC1/ MTFP1/Drp1/ERK1/2 signaling as potential and effective therapeutic targets for treating malignant and metastatic p53compromised tumors [15, 53].”
BackgroundGreger, H. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09761-5 · Cited by 34
“…has been intensified by uncovering their role as direct inhibitors of translation initiation, a key process in protein synthesis (Silvera et al. 2010; Schatz et al. 2011; Bhat et al. 2015; Pelletier et al. 2015; Chu and Pelletier 2015; Chu et al. 2016a; Taylor et al. 2020; Hao et al. 2020).”
BackgroundTargeting DEAD ‐box RNA helicases: The emergence of molecular staples
Naineni, S. K., Robert, F., Nagar, B., & Pelletier, J. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1738 · Cited by 34
“Hence, targeting eIF4F has emerged as an approach by which to inhibit tumor cell proliferation (Bhat et al., 2015).”
BackgroundSelf-citationJuette, M. F., Carelli, J. D., Rundlet, E. J., Brown, A., Shao, S., Ferguson, A., Wasserman, M. R., Holm, M., Taunton, J., & Blanchard, S. C. (2022) · eLife · doi:10.7554/elife.81608 · Cited by 34
“Dysregulated protein synthesis plays a role in several human diseases and is a therapeutic vulnerability in cancer and viral infection (Bhat et al., 2015; Hoang et al., 2021; Xu and Ruggero, 2020).”
BackgroundLiu, Y., Sun, L., Su, X., & Guo, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.038 · Cited by 34
“Given the importance of eIF4E-regulated translation in the development of angiogenesis and various cancers [17,18], we firstly determined whether cercosporamide suppresses eIF4E activity via blocking its phosphorylation at serine 209 to targets HCC and angiogenesis.”
BackgroundKatsha, A. M., Wang, L., Arras, J., Omar, O. M., Ecsedy, J., Belkhiri, A., & El-Rifai, W. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2141 · Cited by 34
“EIF4E-mediated cap-dependent translation regulates several important oncogenes that control stress and inflammatory responses, cell survival, proliferation, and apoptosis (23).”
BackgroundRydzik, A. M., Warminski, M., Sikorski, P. J., Baranowski, M. R., Walczak, S., Kowalska, J., Zuberek, J., Lukaszewicz, M., Nowak, E., W. Claridge, T. D., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx569 · Cited by 32
Translation Regulation in Skin Cancer from a tRNA Point of View
Grafanaki, K., Anastasakis, D. G., Kyriakopoulos, G. C., Skeparnias, I., Georgiou, S., & Stathopoulos, C. (2018) · Epigenomics · doi:10.2217/epi-2018-0176 · Cited by 34
“These interactions often appear derailed and therefore, translation deregulation leading to aberrant production of tumor promoting proteins has been considered a hallmark of cancer [11,12].”
BackgroundXing, W., Qi, Z., Huang, C., Zhang, N., Zhang, W., Li, Y., Qiu, M., Qi, F., & Guo-zhen, H. (2018) · Biology Open · doi:10.1242/bio.037127 · Cited by 33
“Similar to classical oncogenes or tumor-suppressor genes such as eIF4F ( eukaryotic translation initiation factor 4F , Bhat et al., 2015) and DLK1 ( Delta-like 1 homolog , Kawakami et al., 2006), lncRNAs may act as oncogenes or tumor-suppressor genes by altering gene expression (Zhou et al., 2012;…”
Gillen, S. L., Waldron, J. A., & Bushell, M. (2021) · Oncogene · doi:10.1038/s41388-021-02022-x · Cited by 33
Shin, S., Han, M.-J., Jedrychowski, M. P., Zhang, Z., Shokat, K. M., Plas, D. R., Dephoure, N., & Yoon, S.-O. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112868 · Cited by 33
Lineham, E., Spencer, J., & Morley, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0062 · Cited by 32
Reversal of aberrant PI3K/Akt signaling by Salubrinal in a GalT-deficient mouse model
Balakrishnan, B., Nicholas, C., Siddiqi, A. M., Chen, W., Bales, E. S., Feng, M., Johnson, J., & Lai, K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.023 · Cited by 32
“clinical trial for combinational therapy for cancers and also in healing therapy for bone fractures [39, 40].”
BackgroundCencic, R., Im, Y. K., Naineni, S. K., Moustafa-Kamal, M., Jovanovic, P., Sabourin, V., Annis, M. G., Robert, F., Schmeing, T. M., Koromilas, A. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318093121 · Cited by 32
“…in mRNA translation can arise as a consequence of hyperactivation of mitogen - activated protein kinase (MAPK) orphosphatidylinositol - 3 - kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways (10)—both of which indirectly activate the eukaryotic initiation factor (eIF) 4F complex (8).”
BackgroundInfluentialSelf-citationThe mTORC1/S6K/PDCD4/eIF4A Axis Determines Outcome of Mitotic Arrest
Moustafa-Kamal, M., Kucharski, T. J., El-Assaad, W., Abbas, Y. M., Gandin, V., Nagar, B., Pelletier, J., Topisirovic, I., & Teodoro, J. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108230 · Cited by 31
Self-citationeIF2α Phosphorylation Mediates IL24-Induced Apoptosis through Inhibition of Translation
Persaud, L., Zhong, X., Alvarado, G., Do, W., Dejoie, J., Zybtseva, A., Aktas, B. H., & Sauane, M. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0454 · Cited by 31
“This paradigm is consistent with the evolving notion in the field of translational regulation of gene expression, that phosphorylation of eIF2a and the availability of the TC control not only the overall rate of translation, as initially thought, but also have differential effects on the translation and expression of…”
BackgroundSong, J., Yuan, C., Yang, J., Liu, T., Yao, Y., Xiao, X., Gajendran, B., Xu, D., Li, Y., Wang, C., et al. (2018) · FEBS Journal · doi:10.1111/febs.14690 · Cited by 31
Wang, H., Huang, F., Zhang, Z., Wang, P., Luo, Y., Li, H., Li, N., Wang, J., Zhou, J., Wang, Y., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.32489 · Cited by 31
“Accumulating evidence has demonstrated that deregulation of cap-dependent translation promotes cancer initiation and progression by enhancing the expression of a subset of oncogenic proteins such as cyclin D1, survivin, and MMP9 that control cell proliferation, survival, and metastasis, respectively(4).”
BackgroundInhibitors of Eukaryotic Translational Machinery as Therapeutic Agents
Fan, A. P., & Sharp, P. P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01746 · Cited by 31
Zhao, X., Li, J., Liu, Z., & Powers, S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2555 · Cited by 31
“In addition, we found shared epistatic transcriptional changes that are independent of speci fi cdrivergenes,affectingalternativesplicing,cytoskeletalassembly, and protein translation — processes that are commonly altered in cancer (37, 50, 51).”
mTOR-dependent translation drives tumor infiltrating CD8+ effector and CD4+ Treg cells expansion
Conti, B. D. P., Miluzio, A., Grassi, F., Abrignani, S., Biffo, S., & Ricciardi, S. (2021) · eLife · doi:10.7554/elife.69015 · Cited by 31
“Stimulation of protein synthesis occurs through the nutrient growth factor receptor cascades that converge on initiation factors eIF4E, through PI3K-mTORC1, ERK-MNK, and eIF6 ( Loreni et al., 2014 ; Bhat et al., 2015 ).”
Yoo, H. S., Lee, K., Na, K., Zhang, Y. X., Lim, H., Yi, T., Song, S. U., & Jeon, M. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.45 · Cited by 31
“Phosphorylation of two mTORC1 downstream targets, ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), initiates mRNA translation.(3,4) Translation is tightly controlled by the 5ʹ cap-binding eukaryotic translation initiation factor (eIF) complex,(4) and mRNA…”
BackgroundMethodNew half-sandwich ruthenium( ii ) complexes as proteosynthesis inhibitors in cancer cells
Ballester, F. J., Ortega, E., Porto, V., Kostrhunová, H., Davila‐Ferreira, N., Bautista, D. K. M., Brabec, V., Domínguez, F., Santana, M. D., & Ruiz, J. (2019) · Chemical Communications · doi:10.1039/c8cc09211g · Cited by 31
Lelong, E. I. J., Khelifi, G., Adjibade, P., Joncas, F., St-Sauveur, V. G., Paquette, V., Gris, T., Zoubeidi, A., Audet‐Walsh, É., Lambert, J., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac034 · Cited by 30
“Altered expression or activity of components of the eIF4F complex such as EIF4E and EIF4G, have been observed to support cancer cell growth by activating translation initiation of mRNAs encoding key cell cycle regulators, as well as survival and oncogenic factors (Bhat et al. 2015).”
BackgroundA Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia
Datan, E., Minn, I., Xu, P. H., He, Q., Ahn, H.-H., Yu, B., Pomper, M. G., & Liu, J. O. (2020) · iScience · doi:10.1016/j.isci.2020.101536 · Cited by 30
Ho, J. J. D., Cunningham, T. A., Manara, P., Coughlin, C. A., Arumov, A., Roberts, E. R., Osteen, A., Kumar, P., Bilbao, D., Krieger, J. R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109806 · Cited by 30
“Activation of protein synthesis is a critical convergence for oncogenic signals (Bhat et al., 2015; Blagden and Willis, 2011; Robichaud et al., 2019; Truitt and Ruggero, 2016), and targeted manipulation of cap-dependent translation is therefore a highly attractive strategy for cancer therapy (Bhat…”
Martínez-Sáez, E. A., Peg, V., Aznar, A. O., Ricarte, F. M., Camacho, J., Hernández‐Losa, J., Ferreres, J. C., & y Cajal, S. R. (2016) · Cancer Medicine · doi:10.1002/cam4.817 · Cited by 30
“In clinical terms, attempts have been made to inhibit expression of eIF4E with antisense oligonucleotides, which block binding to eIF4G and inhibit phosphorylation with MAPK inhibitors and with ribavirin [21, 32, 35].”
BackgroundWang, G., Li, Z., Li, Z., Huang, Y., Mao, X., Xu, C., & Cui, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.034 · Cited by 30
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.